Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 101

Results For "CROs"

3858 News Found

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Startup | December 05, 2025

Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry

Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions


Senores Pharmaceuticals receives Philippine FDA approval for 10 products
Drug Approval | December 05, 2025

Senores Pharmaceuticals receives Philippine FDA approval for 10 products

Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region


Industry-academia partnership key to advancing R&D agenda, says Dr. Jitendra Singh
R&D | December 05, 2025

Industry-academia partnership key to advancing R&D agenda, says Dr. Jitendra Singh

Growing patent filings and tier-2 innovators reflect expanding national research base


Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
Technology | December 04, 2025

Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies

The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology


Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material
Healthcare | December 04, 2025

Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material

The technology is intended to support imaging-based training, protocol optimisation and surgical planning


Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Clinical Trials | December 04, 2025

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib


Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
Biopharma | December 04, 2025

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor


Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
People | December 04, 2025

Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors


Roche launches first rapid point-of-care test for whooping cough
News | December 04, 2025

Roche launches first rapid point-of-care test for whooping cough

The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms